指南与共识儿科与产科急症

预防母体恒河猴D同种免疫及管理同种免疫妊娠的国家共识声明:改良德尔菲法

National Consensus Statements for the Prevention of Maternal Rhesus D Alloimmunization and Management of Alloimmunized Pregnancies: A Modified Delphi Process.
指南 / 共识 · J Obstet Gynaecol Can · 2025-09-22
一句话结论加拿大46名多学科专家通过改良德尔菲法就47项实践达成共识,其中15项高危产科场景声明获得共识(Cronbach α=0.94)。

该共识由加拿大46名多学科专家参与改良德尔菲法,对47项关于同种免疫筛查与管理的实践进行投票,共进行3轮调查后全部声明达成共识(Cronbach α=0.94)。本文呈现其中15项涉及高危产科场景的声明,涵盖临床显著抗体检测(如Kell)、抗体滴定频率、父亲表型分型、胎儿基因分型、多学科照护以及异位妊娠、葡萄胎妊娠及侵入性胎儿检测或治疗后RhIG的给药。共识旨在提供国家标准化建议以指导检测实践、减少不必要检测、优化资源并改善患者照护。结论指出需通过涵盖临床诊室、医院急诊科和产房单元的广泛教育项目来推动实践改变。

要点

  • 46名加拿大专家经3轮投票对47项实践全部达成共识,Cronbach α=0.94。
  • 15项高危产科声明涉及临床显著抗体检测(如Kell)、抗体滴定频率、父亲表型分型、胎儿基因分型、多学科照护。
  • 声明涵盖异位妊娠、葡萄胎妊娠及侵入性胎儿检测或治疗后RhIG的给药。
  • 共识目标为减少不必要检测、优化资源并改善患者照护。
  • 推动实践改变需涵盖临床诊室、医院急诊科和产房单元的广泛教育项目。

适用人群与场景

  • 有同种免疫风险或已发生同种免疫的妊娠患者。
  • 高危产科场景,包括异位妊娠、葡萄胎妊娠及接受侵入性胎儿检测或治疗者。

处置流程与药物剂量

  • 对高危患者评估临床显著抗体(如Kell)。
  • 进行抗体滴定频率、父亲表型分型、胎儿基因分型及多学科照护。
  • 在异位妊娠、葡萄胎妊娠及侵入性胎儿检测或治疗后给予RhIG。

研究设计与关键结果

  • 46名加拿大专家参与改良德尔菲法,对47项实践进行投票,3轮后全部声明达成共识(Cronbach α=0.94)。
  • 本文呈现15项高危产科场景声明,涉及临床显著抗体检测(如Kell)、抗体滴定频率、父亲表型分型、胎儿基因分型、多学科照护及RhIG给药。

证据类型、等级与局限

  • 证据类型:改良德尔菲法共识。
  • 共识定义:Cronbach α >0.95,最多3轮投票。
  • 实际达成:3轮后Cronbach α=0.94。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 共识提供关于预防和管理RhD同种免疫及临床显著抗体最佳实践的指导,以优化RhIG使用并支持临床单元。
  • 推动实践改变需要涵盖临床诊室、医院急诊科和产房单元的广泛教育项目。

指南或共识出处

  • 国家共识声明:预防母体恒河猴D同种免疫及管理同种免疫妊娠:改良德尔菲法(J Obstet Gynaecol Can)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: National stakeholders developed guidance statements regarding controversial aspects of perinatal testing and management of pregnancies at risk of or affected by alloimmunization. The objective was to create national, standardized recommendations to guide testing practices, reduce unnecessary testing, optimize resources, and improve patient care.

METHODS: A total of 46 multidisciplinary Canadian experts participated in an iterative Delphi process to reach consensus on 47 practices regarding all aspects of screening and management of pregnant persons at risk of alloimmunization. The panel rated their agreement on a 5-point Likert scale. After each round, panellists voted again on the statements until consensus was achieved, defined as a Cronbach α >0.95 in a maximum of 3 voting rounds. Fifteen of the 47 statements pertaining to high-risk obstetrical scenarios are presented.

RESULTS: A total of 46 experts completed all rounds of voting. Consensus was achieved after 3 survey rounds (Cronbach α = 0.94) for all statements. The 15 statements reaching consensus addressed general issues pertinent to the evaluation of the high-risk patient, including testing for clinically significant antibodies (e.g., Kell), antibody titration frequency, paternal phenotyping, fetal genotyping, multidisciplinary care, and administration of RhIG following clinical situations such as ectopic or molar pregnancy and after invasive fetal testing or therapy.

CONCLUSIONS: The consensus document provides guidance regarding best practices for prevention and management of alloimmunization to RhD and clinically significant antibodies to optimize RhIG usage and support clinical units. To effect practice change, knowledge translation of this consensus will require a broad educational program involving clinical offices, hospital emergency departments, and birthing units.

来源:J Obstet Gynaecol Can,查看原文。版权归原作者所有。

参考来源

  1. Robitaille N, Lieberman L, Clarke G, et al. National Consensus Statements for the Prevention of Maternal Rhesus D Alloimmunization and Management of Alloimmunized Pregnancies: A Modified Delphi Process. J Obstet Gynaecol Can. 2025. PMID: 40992621. doi:10.1016/j.jogc.2025.103113

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。